FDA	United States Food and Drug Administration
CTLA-4	cytotoxic T-lymphocyte-associated protein 4
PD-1	programmed cell death protein 1
ASCO	American Society of Clinical Oncology
CTCAE	criteria for adverse events
ORR	overall response rate
CR	complete remission
PR	partial remission
SD	stable disease
DCR	disease control rate
OS	overall survival
PFS	progression-free survival
TRAE	treatment related adverse event
irAE	immune-related adverse event
CPI	immune checkpoint inhibitor
IL-2	interleukin-2
PEG	polyethylene glycol
T-VEC	talimogene laherparepvec
GM-CSF	granulocyte-macrophage colony-stimulating factor
MBM	melanoma brain metastases
UM	uveal melanoma
MAPK	mitogen-activated protein kinase
MHC	major histocompatibility complex
TCR	T-cell receptor
TAA	tumor-associated antigens
DC	dendritic cell
NK	natural killer cells
Treg	T regulatory cells